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that produced a time- and voltage-dependent inhibition of L-type (but not T-type) Ca 2+-channel current in GH, cells. 
The results suggest that this fraction contains an endogenous substance that binds directly to slowly-inactivating Ca*+ 
channels and thereby inhibits current flow. 
Endogenous ligand; Modulator; 1,4_Dihydropyridine; Nitrendipine; Ca2+ antagonist; Receptor binding; (Brain) 
1. INTRODUCTION 
There are several sites on L-type Ca2+ channels 
at whi& WW@+X& 
. 1 L dmgi +mfi @s&~~~~K!F~~~ 
with high affinity [ 1,2]. The density of these sites 
can be modulated by treating animals chronically 
with various Ca’+ -channel ligands [2-41. Synthetic 
pathways have been proposed that may occur 
spontaneously in vivo to produce DHPs [5]. These 
findings, along with the existence of BAY K8644 
and related drugs that ‘activate’ Cal’ channels., 
support the idea that endogenous substances 
analogous to DHps 0~ r&al& 6~32~ may exist 
1671. 
A few preliminary reports suggest he existence 
Abbreviations: DHP, 1,4-dihydropyridine-type Ca’+-channel 
antagonist; FBI, <l kDa inhibitory fraction from brain; 
HPLC, high-performance liquid chromatography; MBP, 
myelin basic protein; SEC, size exclusion chromatography; 
TFA, trifluoroacetic acid 
of endogenous substances that modify DHP 
binding [g-11] (for review, see [2]). Recently, 
brain fractions that inhibit [3H]DHP binding and 
45P ~~rir,i;irm~,~~"~,~~~r~~'~f~,~~5. ?Z~ZT~~T~IX&L 
to previous reports, we describe the isolation of a 
fraction from brain that exerts specific, reversible, 
and voltage-dependent inhibition of L-type 
Ca2+-channel current under voltage-clamp con- 
ditions. 
2. MATERIALS AND METHODS 
2. I. PurrjGa0tin procedures 
Fresh bovine brains were obtained from a local 
slaughterhouse and lyophiiized bovine brain From Barlingron 
Bio-Medical Corp., NY. Typically, lo-15 kg of fresh or 
0. I- 1 kg of lyophilized calf brain was homogenized (Polytron, 
X&ID@ in ati~?I by the merhob 03 Bennerr 5121 as rnoK>%h . . 
64 Q&&I eL a<. ($35. T+R %WmVgW&% ‘*as -++X+& tij c:%%- 
trifugation (16000 x g for 45 min) and the supernatant was ex- 
tracted with 2 vols of petroleum ether. The aqueous phase was 
adjusted to pH 2 with NaOH and subjected to ultrafiltration on 
a Pellicon apparatus (Millipore) equipped with a ~30 kDa cuf- 
off membrane. The ultrafiltrate was then subjected to 
preparative reverse-phase HPLC on an octadecylsilane column 
(5.7 x 30 cm) employing a gradient of O-70% acetonitrile in 
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0.1% TFA over 1.5 h at a flow rate of 150 ml/min. Fractions 
were collected, aliquots were dried (Speed Vat, Savant) and 
tested for their ability to inhibit the specific binding of 
[3H]DHP to rat cardiac membranes. Fractionation of the active 
region from this column was performed on a BioSil TSK-250 
column (7.5 x 300 mm; BioRad) utilizing a mobile phase of 
40% acetonitrile/O. 1% TFA at a flow rate of 0.5 ml/min. Ali- 
quots were dried and assayed for [3H]DHP binding inhibitory 
activity. The activity that elutes with an apparent molecular 
mass of < 1 kDa is herein denoted as FBI. 
2.2. Ligand binding 
Inhibition of binding of [‘H]DHPs (nitrendipine or PN 
200-l 10; New England Nuclear, Boston) was carried out at 
25°C in 0.25 to 2.5 ml assay volumes as described previously 
[8]. The percent inhibition of binding was independent of the 
‘H-ligand used. Protease inhibitors (1 pM aprotinin; 50 gM 
benzamidine; 50 pM leupeptin) were added in some assays (see 
section 3). [‘H]Ouabain and [3H]saxitoxin binding were deter- 
mined as previously described [14,15]. 
2.3. Electrophysiology 
Electrophysiological effects of fractions on GHj cells were 
determined by the methods of Cohen and McCarthy previously 
used to study the effect of nimodipine in our laboratory 1161. 
Fractions were added either extracellularly or into the dialysis 
solution of the recording pipette. The whole cell variant of the 
patch-electrode voltage-clamp technique was used. Tail-current 
analysis with curve peeling was used to separate the contribu- 
tions of the two types of Cal’ channels. 
2.4. Other methods 
Inorganic phosphate and lipids were determined by published 
methods [17,18]. 1 pU activity is defined as that amount of ac- 
tivity which inhibits the specific binding of f3H]DHP (0.2 nM 
[‘H]PN 200-I 10 or 1 nM [3H]nitrendipine) to rat cardiac mem- 
branes by 50% in a 0.25 ml assay volume. Unlabeled 
nimodipine was the standard displacer. 
3. RESULTS AND DISCUSSION 
Fractions eluting at 30-35070 acetonitrile from 
the preparative reverse-phase Cl8 column in- 
hibited [3H]DHP binding (fig. 1). Electrophysio- 
logical measurements were subsequently per- 
formed to more stringently address the question of 
whether the activity was DHP-like in nature. Ac- 
tive fractions upon intracellular dialysis in the 
pipette solution produced time- and voltage- 
dependent block of L-type Ca2+-channel current in 
GH3 cells. The characteristics of this inhibition 
were consistent with those seen for DHP as deter- 
mined by tail-current analysis. However, the frac- 
tion was inactive when added to the extracellular 
bathing solution. 
The fraction produced a concentration- 
dependent inhibition of [3H]DHP binding to car- 
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disc and brain membranes. Polyacrylamide elec- 
trophoresis in the presence of SDS showed the 
presence of two bands with relative molecular 
masses of 18 and 20 kDa. Amino acid analysis and 
tryptic maps of the 18 kDa protein matched that of 
MBP. The I&, value for inhibition of [3H]DHP 
binding to cardiac membranes of the 18 kDa pro- 
tein was =4,~uM, the same as that observed for 
commercially available preparations of MBP. 
Tryptic mapping confirmed that most of the 
18 kDa protein was MBP. Commercially available 
MBP inhibited [3H]DHP binding but did not block 
the L-type Ca2+ -channel current, suggesting that 
some other substance was co-purifying with MBP. 
Indeed, further purification of this fraction by 
SEC in the presence of 40% acetonitrile revealed 
the presence of two inhibitors of DHP binding. 
One was MBP and the other, a small molecular 
mass fraction, FBI, with an apparent size of 
< 1 kDa (fig.2). This low molecular mass fraction, 
in contrast to MBP, completely inhibited [3H]DHP 
binding. The inhibition curve obtained had an ap- 
parent Hill slope of >2, suggesting that the inhibi- 
tion was not due to a simple 1: 1 direct binding to 
the DHP recognition site. FBI but not the MBP- 
containing fraction, was capable of blocking the L- 
type Ca2+ -channel current. Thus, MBP dissociated 
from FBI by SEC, was now inactive on 
Ca2+-channel current as previously noted for com- 
mercial preparations of MBP. In addition, SEC- 
purified FBI was capable of blocking L-type 
Ca2+-channel current when applied extracellularly 
(fig.3). A prepulse of variable length at -40 mV 
from a hyperpolarized potential (- 90 mV) was 
followed by a strong depolarization to assay for 
current through available L-type channels upon 
repolarization: ~10 pU of FBI activity was applied 
extracellularly. The time constant for the decrease 
in current was 47.8 s for the control and 8.45 s for 
the FBI-treated GH3 cells. 
The chemical nature of FBI was explored by 
analysis for amino acids, fatty acids and certain 
other lipids. High-sensitivity amino acid analysis 
failed to detect amino acids in this fraction. Based 
on the amount of activity used, it can be concluded 
that either the sample is free of amino acids, or it 
contains a peptide that is considerably more potent 
than nimodipine. Those fatty acids that are known 
to inhibit [3H]DHP binding at 100 to 2OOpM ([18] 
and unpublished) were not present in this fraction. 
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Fig. 1. Preparative reverse-phase chromatography of a preparation from an acid extract of fresh calf brains. The hatch bars denote 
the region containing FBI and MBP as determined by [3H]DHP binding and subsequent SEC. 
FBI did not inhibit [3H]ouabain or [3H]saxitoxin 
binding to brain membranes in amounts that in- 
hibit [3H]DHP binding. The lack of effect on 
[3H]ouabain binding is of particular interest 
because it indicates that certain nonesterified fatty 
acids and lysophospholipids which are known to 
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Fig.2. Separation of the low molecular mass inhibitory fraction, 
FBI, from myelin basic protein by size exclusion 
chromatography. 
inhibit ouabain binding [20,21], are not present in 
significant amounts in FBI. 
FBI appears to be different from the other brain 
fractions that have been reported to inhibit 
[3H]DHP binding. The 1.2 kDa fraction of Eber- 
sole et al. [I I] did not inhibit [3H]DHP binding to 
heart membranes, the fraction of Sanna and Han- 
bauer [ 121 inhibited both L- and T-type Ca2+ chan- 
nels, and is likely to be an acidic peptide (personal 
communication), and that of Thayer et al. [12] was 
reported to be of 5 to 10 kDa. These characteristics 
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Fig.3. L-type calcium-channel tail currents in GHs cells exhibit 
time- and voltage-dependent onset of block by FBI at - 40 mV. 
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differentiate FBI from the other factors. In sum- 
mary, we report for the first time the isolation of 
a < 1 kDa fraction that specifically inhibits the L- 
type Ca2+ -channel current and [3H]DHP binding. 
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